NICE gives final opinion approving use of RoActemra in giant cell arteritis.- Roche/Chugai.
In final guidance, the National Institute of Health and Care Excellence has given its support for the use of RoActemra (tocilizumab) from Roche/Chugai, for the treatment of eligible patients with giant cell arteritis (GCA). According to data from the GiACTA clinical trial, after having RoActemra plus a tapering course of glucocorticoids for one year, more people stay in remission and need lower doses of glucocorticoids compared with people having glucocorticoids alone.
NICE is recommending funding for one year�s treatment with the drug for patients who suffer flares of their GCA or may not respond fully to steroids, as their disease is most difficult to control.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins